Bullish Case: Icahn's stake (~$19 cost basis), a live strategic review, expiring poison pill, and buyers like Mavis anchoring $21–26+ real-estate-value scenarios give MNRO a credible M&A path from $14.30. Call volume dominates 98% over puts and Helium's density assigns more weight to $15–17.50 than the market's $12.50 center — consistent with takeover/recovery optionality at 1.9x book.

Bearish Case: Comps deterioration, store closures, and refinancing risk persist; the return surface holds deep negative mass (-10% to -67% tails) and market density centers at $12.50. Near-term IV remains extreme (132% Nov upper wing vs. 44% lower), meaning the market still prices crash risk. Icahn catalysts have failed to materialize for 12 months; a weak fiscal Q2/Q3 update could re-rate shares toward $10–12.

Potential Outcomes:

1. 30% Rangebound $13–15.50 into Jan 16 — no deal; IV decays slowly (falsified if $15 call OI surges or breaks $12.50).
2. 25% Strategic sale/offer $19–24 — poison-pill expiry, 13D/board news, Mavis/PE bid (verify filings).
3. 20% Operational recovery — fiscal Q2/Q3 comps stabilize → $15–17.
4. 18% Earnings/guide miss → $10–12.50; Nov 132% wing IV validates crash pricing.
5. 7% Liquidity/credit tail <$10; deep-put IV >200%.

October 29, 2026